Share ownership Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			After hours 05:11:38 pm
29.89 ^USD	-0.10%		29.78	-0.35%

Dec. 12	Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating	MT
Dec. 12	Rate Cuts Can't Buy Confidence

Share class: Moderna, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	384,817,811	348,169,765 ( 90.48 %)	0	90.48 %

Major shareholders: Moderna, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.54 %	41,185,295	10.54 %	1 070 M $
BlackRock Advisors LLC 6.05 %	23,641,193	6.05 %	614 M $
Stéphane Bancel 5.62 %	21,957,536	5.62 %	570 M $
Baillie Gifford & Co. 5.591 %	21,846,666	5.591 %	568 M $
STATE STREET CORPORATION 4.379 %	17,108,595	4.379 %	444 M $
Fidelity Management & Research Co. LLC 3.149 %	12,304,297	3.149 %	320 M $
Eaton Vance Management 2.55 %	9,962,232	2.55 %	259 M $
Geode Capital Management LLC 2.367 %	9,249,352	2.367 %	240 M $
Invesco Advisers, Inc. 2.103 %	8,216,163	2.103 %	213 M $
Thélème Partners LLP 2.065 %	8,068,810	2.065 %	210 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	58.65%
Other	7.68%
Individuals	6.76%
State Street Corp.	4.38%
Merck & Co., Inc.	0.59%
Schweizerische Nationalbank	0.17%
Manulife Financial Corp.	0.12%
Governments	0.1%
SEI Investments Co.	0.04%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Fifth Third Bancorp	0.01%
The Bank of Nova Scotia	0.01%
Meitav Investment House Ltd.	0.01%
Unknown	21.46%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	54.14%
United Kingdom	12.15%
Individuals	6.76%
Switzerland	1.35%
Canada	1.31%
Norway	0.9%
France	0.45%
Australia	0.22%
Hong Kong	0.19%
Luxembourg	0.17%
Sweden	0.15%
Japan	0.15%
Spain	0.13%
Germany	0.1%
Ireland	0.1%
Netherlands	0.07%
China	0.04%
Czech Republic	0.03%
Singapore	0.03%
Israel	0.02%
Italy	0.02%
New Zealand	0.01%
Puerto Rico	0.01%
Belgium	0.01%
Denmark	0.01%
Cayman Islands	0.01%

Based on 1000 largest holdings

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company